Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.